reptides › libido › pt-141

pt-141

the FDA-approved sex peptide for acquired generalized HSDD in premenopausal women. off-label male use is a separate evidence lane.

tier A · libido · FDA '19 Vyleesi · HSDD

verdict

FDA-approved as Vyleesi for HSDD in premenopausal women. the louder cultural use case (male PDE5 non-responders) is off-label and being formally tested.

if you're asking how PT-141 differs from sildenafil — different mechanism, different problem. sildenafil acts on peripheral vasculature and enables erection. PT-141 acts on MC4R in the hypothalamus and limbic regions and addresses desire upstream. peak effect lands 45-90 minutes after a subcutaneous dose, lasts 4-6 hours. RECONNECT 1 and 2 (n=1,247) met co-primary endpoints in women with acquired generalized HSDD.

if you're asking about off-label male use — this is where most of the cultural attention sits. a small phase II in male PDE5 non-responders showed 34% achieving erections vs 9% on placebo. Palatin reopened the lane in 2024 with an open-label phase 2 and has projected phase 3 recruitment and topline timing. until results are posted, the public record is company guidance plus that older phase 2, not approved drug data.

if you came in worried about the side-effect profile — 40% of users get nausea on the first dose; it usually attenuates with subsequent use. transient blood pressure changes and hyperpigmentation (the MC1R cross-talk) are documented. response is heterogeneous in a clinically meaningful way: responders describe dramatic effects, non-responders notice almost nothing. researchers have questioned whether the average effect size in the on-label trials is clinically meaningful even when the endpoint is met.

based on published evidence and disclosed clinical practice. not medical advice. dose and protocol conversations belong with a clinician.

why A-tier

FDA-approved for premenopausal women with HSDD as Vyleesi since June 2019. mechanism, central melanocortin MC4R agonism, targets a completely different pathway from PDE5 inhibitors like sildenafil. unlike most peptides on this list, PT-141 has a completed phase III program (RECONNECT 1 + 2, n=1,247) and an active FDA approval. widely used off-label for male sexual dysfunction, especially PDE5-inhibitor non-responders. A-tier because FDA-approved for a specific indication but the broader use case most people encounter is off-label, and effect sizes in the approved indication have been legitimately questioned by researchers.

the core tension

The mechanism was discovered by accident during tanning peptide research. The approval took 20 years. The clinical effect is real but narrow, and the off-label use most people associate with it isn't the approved one.

what it is

bremelanotide, a cyclic heptapeptide and non-selective melanocortin receptor agonist. FDA-approved as Vyleesi in June 2019 for hypoactive sexual desire disorder in premenopausal women. structurally one functional group away from melanotan II, which is exactly where it came from.

what it does

activates MC4R in the hypothalamus and limbic regions to drive sexual desire centrally, which is mechanistically distinct from PDE5 inhibitors that act on peripheral vasculature. sildenafil enables erection; PT-141 addresses desire upstream. peak effect lands 45 to 90 minutes after a subcutaneous dose, lasts 4 to 6 hours.

origin

Palatin Technologies in Cranbury, New Jersey, isolated from melanotan II metabolite work in the late 1990s. FDA halted the intranasal ED program in 2007 over blood pressure. Palatin pivoted to subcutaneous and female HSDD, AMAG licensed it in 2017 for $60M upfront, FDA approved Vyleesi in 2019. roughly two decades from accident to approval.

why researchers are interested

RECONNECT 1 and 2 enrolled 1,247 women and met co-primary endpoints. it fills a treatment gap PDE5 inhibitors cannot touch. peptide clinics adopted it heavily off-label for male PDE5 non-responders, where a small phase II showed 34% achieving erections versus 9% on placebo. responders often describe the subjective effect as substantially stronger than expected.

does it work

yes, but narrowly and with caveats. the on-label HSDD effect is real but researchers have legitimately questioned whether the average effect size is clinically meaningful, and 40% of users get nausea on the first dose. response is heterogeneous: people who respond report dramatic effects, people who do not respond notice almost nothing. the off-label male use case is where most of the cultural attention sits, and that one is not FDA-sanctioned. Palatin reopened that lane in 2024 with an open-label phase 2 study in PDE5i non-responders and later projected phase 3 recruitment and topline timing, but the public record should be treated as company guidance until results are posted. Drug-grade evidence for a narrow indication, plus a louder off-label story that is being formally tested.

claims vs the data

  • FDA-approved for sexual desire disorder — supported — Vyleesi approved June 21 2019 for premenopausal women with acquired generalized HSDD. first and still one of the only FDA-approved as-needed treatments for this indication.
  • works for men with erectile dysfunction — partially true — phase II data in sildenafil non-responders: 34% achieved erections with PT-141 vs 9% placebo. not FDA-approved for men; off-label use is widespread.
  • increases sexual desire centrally, not just physical arousal — supported — acts at MC4R in hypothalamus and limbic regions. different mechanism from PDE5 inhibitors (which work on peripheral vasculature).
  • raises blood pressure — supported — dose-dependent transient BP increase (mean +6 mmHg systolic, +3 diastolic) resolving within 12 hours. contraindicated in uncontrolled hypertension.
  • causes skin hyperpigmentation — partially true — rare at approved dosing. more common with frequent use (>8 doses/month) due to MC1R activation. may not resolve on discontinuation.
  • effect size is large — contradicted — researchers have questioned whether the RECONNECT effect sizes are clinically meaningful. benefits may be modest relative to the side effect profile.
  • PT-141 works like a universal libido switch — overreach — Bremelanotide is approved for acquired, generalized HSDD in premenopausal women. The approval does not prove universal libido enhancement, male performance use, or recreational reliability, and the label risk package includes nausea, flushing, blood-pressure effects, injection reactions, and hyperpigmentation.

key facts

  • molecular formula: C₅₀H₆₈N₁₄O₁₀
  • molecular weight: 1025.2 g/mol
  • amino acids: 7 (cyclic heptapeptide)
  • half-life: ~2 hours (peak central effect 45-60 min)
  • type: non-selective melanocortin receptor agonist
  • CAS: 189691-06-3
  • 2019 FDA approval (vyleesi)
  • 1,247 phase III enrollment (RECONNECT)
  • 40% report nausea on first dose
  • 1.75mg approved subcutaneous dose

frequently asked questions

What is PT-141?

PT-141 is bremelanotide, a synthetic melanocortin-4 receptor (MC4R) agonist derived from research on Melanotan II. FDA-approved as Vyleesi in 2019 for hypoactive sexual desire disorder (HSDD) in premenopausal women.

What does PT-141 do?

PT-141 activates central MC4R pathways that modulate sexual arousal and desire. Unlike PDE5 inhibitors (sildenafil, tadalafil), it works through the central nervous system rather than peripheral vascular effects. Clinical trials demonstrated efficacy in premenopausal female HSDD. Male use is off-label and supported by a separate, thinner evidence lane.

How is PT-141 typically administered?

The FDA-approved Vyleesi label uses a 1.75 mg single-dose autoinjector at least 45 minutes before anticipated sexual activity, with a maximum of 8 doses per month and no more than one dose per 24 hours. That label applies to acquired generalized HSDD in premenopausal women, not male or performance use.

What are the side effects of PT-141?

Common side effects include nausea, flushing, injection-site reactions, headache, and transient blood pressure elevation. Less common: focal skin hyperpigmentation with repeated use, particularly on the face, gingiva, and breasts. Contraindicated in users with uncontrolled hypertension or known cardiovascular disease.

Is PT-141 FDA approved?

Yes, as Vyleesi (bremelanotide), approved in 2019 for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Not approved for men, postmenopausal women, or any other indication.

How much does PT-141 cost?

Branded Vyleesi retails around $500-1000 per month without insurance. Research-grade bremelanotide on the grey market is not an FDA-reviewed product and is not for human use.

related peptides

  • melanotan-ii — the parent compound, PT-141 is its arousal metabolite
  • kisspeptin-10 — other main peptide pipeline for HSDD, different (endogenous) mechanism
  • oxytocin — social/sexual peptide with overlapping research communities

reptides grades the research record and cites the literature behind every call. research reference only; not medical advice.